Pfitzenmaier Jesco, Vessella Robert, Higano Celestia S, Noteboom Jennifer L, Wallace David, Corey Eva
Department of Urology, University of Washington, Seattle, Washington 98195, USA.
Cancer. 2003 Mar 1;97(5):1211-6. doi: 10.1002/cncr.11178.
Approximately 60-70% of patients with advanced prostate carcinoma (CaP) suffer from cachexia, one of the most devastating conditions associated with advanced malignant disease. The pathophysiology of cachexia is multifactorial, and several cytokines, such as tumor necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1), IL-6, and IL-8, may be involved. The objective of the current study was to determine whether cachexia associated with advanced CaP is accompanied by increased serum levels of TNFalpha, IL-1beta, IL-6, and IL-8.
The levels of TNFalpha, IL-1beta, IL-6, IL-8, and prostate specific antigen (PSA) were examined in serum samples from normal donors (n = 10 donors), from patients with organ-confined CaP (n = 19 patients), from patients with advanced CaP without cachexia (n = 17 patients), and from patients with cachectic CaP (n = 26 patients). DPC Immulite and Abbott IMx Total-PSA assays were used to determine cytokine and PSA levels, respectively.
Levels of TNFalpha, IL-6, and IL-8 were elevated significantly in the group of patients with advanced, cachectic CaP compared with patients who were without cachexia. In the cachectic patients, levels of TNFalpha were correlated positively with IL-8, and there was no correlation between PSA levels and any of the cytokine levels. IL-1beta levels were below the limit of detection in all samples.
The current results show that levels of TNFalpha, IL-6, and IL-8 were increased in CaP patients with cachexia. Increased levels of these cytokines were not correlated with PSA levels, suggesting that they are regulated by a mechanism that is independent of PSA synthesis. Additional fundamental research is needed to determine the mechanisms involved and to identify potential therapeutic targets in patients with cachexia.
大约60%-70%的晚期前列腺癌(CaP)患者会出现恶病质,这是与晚期恶性疾病相关的最具破坏性的病症之一。恶病质的病理生理学是多因素的,几种细胞因子,如肿瘤坏死因子α(TNFα)和白细胞介素1(IL-1)、IL-6和IL-8,可能与之有关。本研究的目的是确定与晚期CaP相关的恶病质是否伴有血清TNFα、IL-1β、IL-6和IL-8水平的升高。
检测了正常供体(n = 10名供体)、器官局限性CaP患者(n = 19名患者)、无恶病质的晚期CaP患者(n = 17名患者)以及恶病质性CaP患者(n = 26名患者)血清样本中的TNFα、IL-1β、IL-6、IL-8和前列腺特异性抗原(PSA)水平。分别使用DPC Immulite和雅培IMx总PSA检测法来测定细胞因子和PSA水平。
与无恶病质的患者相比,晚期恶病质性CaP患者组中TNFα、IL-6和IL-8水平显著升高。在恶病质患者中,TNFα水平与IL-8呈正相关,PSA水平与任何细胞因子水平之间均无相关性。所有样本中的IL-1β水平均低于检测限。
目前的结果表明,恶病质性CaP患者中TNFα、IL-6和IL-8水平升高。这些细胞因子水平的升高与PSA水平无关,表明它们受一种独立于PSA合成的机制调节。需要进行更多的基础研究来确定其中涉及的机制,并确定恶病质患者的潜在治疗靶点。